Trial Profile
A Phase I Open-label Dose-escalation Study of Continuous Twice-daily Oral Treatment With BIBF 1120 in Japanese Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jul 2014
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 14 Jul 2014 New trial record